Hirano Harukazu
Koyo Seikyo Clinic Fukui Health Cooperative Association (FHCA) Fukui Japan.
J Gen Fam Med. 2024 Mar 26;25(3):140-145. doi: 10.1002/jgf2.688. eCollection 2024 May.
This study aimed to assess the changes in anti-spike protein IgG antibody titer over time following mRNA vaccination (BNT162b2) against severe acute respiratory syndrome coronavirus 2.
We monitored IgG levels in 23 medical care workers (MCWs) for up to 3 months after administering the third dose of BNT162b2. Blood samples were periodically collected from all participants.
Following the third dose, the median antibody titer increased to 252 and 327% compared with antibody levels at 1 and 3 months after the second dose, respectively. Additionally, compared with 1 month after the second dose, the median antibody titer decreased to 30.2 and 9.8% at 3 and 6 months, respectively, and to 39.1% at 3 months, compared with 1 month after the third dose.
Antibody levels declined quickly after the second dose but declined more slowly after the third dose, showing a booster effect. This study provides insights into the immunogenicity of booster doses and time intervals for booster vaccination strategies.
本研究旨在评估接种严重急性呼吸综合征冠状病毒2的mRNA疫苗(BNT162b2)后,抗刺突蛋白IgG抗体滴度随时间的变化。
我们在23名医护人员接种第三剂BNT162b2后的3个月内监测其IgG水平。定期采集所有参与者的血样。
接种第三剂后,抗体滴度中位数分别比第二剂后1个月和3个月时的抗体水平提高了252%和327%。此外,与第二剂后1个月相比,抗体滴度中位数在3个月和6个月时分别降至30.2%和9.8%,与第三剂后1个月相比,在3个月时降至39.1%。
抗体水平在第二剂后迅速下降,但在第三剂后下降较慢,显示出加强免疫效果。本研究为加强免疫剂量的免疫原性和加强免疫接种策略的时间间隔提供了见解。